...
首页> 外文期刊>Hepatology international >Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection
【24h】

Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection

机译:临床和静脉分子分类器,用于预测肝细胞癌预后和手术切除后复发

获取原文
获取原文并翻译 | 示例
           

摘要

Background Approximately 50% hepatocellular carcinoma (HCC) patients die within 5 year after surgical resection. The present staging systems do not fully allow to accurately predict the HCC prognosis and recurrence. This study aimed to identify clinicopathological characteristics and molecular markers to establish classifiers to predict the 5-year overall survival (OS) and the 3-year recurrence in HCC patients post-operatively. Methods We enrolled 647 HCC patients from two institutions, underwent surgical resection and divided the patients into one training and two validation cohorts. Clinicopathologic characteristics and tumor protein expression of 29 biomarkers by immunohistochemical (IHC) analysis were used to develop and validate a prognostic and a recurrent classifier, using the maximum relevance minimum redundancy algorithm jointly with the multivariable regression method. Results The prognostic classifier distinguished HCC patients into high- and low-probability survival groups with significant differences in 5-year OS rate in all three cohorts (training cohort: 57.36% vs. 22.97%; p < 0.0001; internal validation cohort: 61.90% vs. 28.85%; p < 0.0001; independent validation cohort: 64.28% vs. 22.45%; p < 0.0001). The recurrent classifier also demonstrated good discrimination in all three cohorts. Conclusion This study presented a prognostic classifier and a recurrent classifier using clinicopathologic and IHC characteristics. The developed classifiers stratified HCC patients into high- and low-probability survival or recurrent groups, which can help clinicians judge whether adjuvant therapy is beneficial post-operatively.
机译:背景技术约50%的肝细胞癌(HCC)患者在手术切除后5年内死亡。目前的分期系统没有完全允许准确预测HCC预后和复发。本研究旨在鉴定临床病理特征和分子标志物,建立分类剂以预测5年的总生存(OS)和术后HCC患者的3年复发。方法我们注册了647名HCC患者,从两所机构进行,接受手术切除,并将患者分成一项培训和两个验证队列。通过免疫组织化学(IHC)分析使用29个生物标志物的临床病理特性和肿瘤蛋白表达用于开发和验证预后和复发分类器,使用多变量回归法共同相关最小冗余算法。结果预后分类机构尊重HCC患者的高概率存活群体,所有三个队列中的5年OS率差异显着差异(培训队列:57.36%与22.97%; P <0.0001;内部验证队列:61.90%与28.85%; P <0.0001;独立验证队列:64.28%与22.45%; P <0.0001)。经常性分类器还表现出所有三个队列的良好歧视。结论本研究介绍了使用临床病理学和IHC特性的预后分类器和复发分类器。开发的分类剂分层HCC患者进入高概率的存活或复发组,可以帮助临床医生判断辅助治疗是否可操作地是有益的。

著录项

  • 来源
    《Hepatology international》 |2019年第6期|共11页
  • 作者单位

    Zhejiang Univ Affiliated Hosp 1 Sch Med Dept Pathol Hangzhou 310003 Zhejiang Peoples R China;

    Zhejiang Univ Affiliated Hosp 1 Sch Med Dept Pathol Hangzhou 310003 Zhejiang Peoples R China;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Hangzhou 310020 Zhejiang Peoples R China;

    Zhejiang Univ Affiliated Hosp 1 Sch Med Dept Pathol Hangzhou 310009 Zhejiang Peoples R China;

    Zhejiang Univ Affiliated Hosp 1 Sch Med Dept Pathol Hangzhou 310003 Zhejiang Peoples R China;

    Zhejiang Univ Affiliated Hosp 1 Sch Med Dept Pathol Hangzhou 310003 Zhejiang Peoples R China;

    Zhejiang Univ Affiliated Hosp 1 Sch Med Dept Pathol Hangzhou 310003 Zhejiang Peoples R China;

    Zhejiang Univ Affiliated Hosp 1 Sch Med Dept Pathol Hangzhou 310003 Zhejiang Peoples R China;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Hangzhou 310020 Zhejiang Peoples R China;

    Zhejiang Univ Sir Run Run Shaw Hosp Sch Med Hangzhou 310020 Zhejiang Peoples R China;

    Zhejiang Univ Affiliated Hosp 1 Sch Med Div Hepatobiliary &

    Pancreat Surg Dept Surg Hangzhou;

    McMaster Univ Fac Hlth Sci Dept Pathol &

    Mol Med Hamilton ON L8S 4K1 Canada;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 消化系及腹部疾病;
  • 关键词

    Hepatocellular carcinoma; Prognosis; Recurrence; Predicting classifiers; Immunomarkers;

    机译:肝细胞癌;预后;再次发生;预测分类器;免疫标志物;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号